Daiichi Sankyo is set to restructure its wholly-owned Kitasato Daiichi Sankyo Vaccine subsidiary into a specialised manufacturing division to enhance stable production and quality.

In August this year, Daiichi Sankyo will establish Daiichi Sankyo Biotech as a wholly owned subsidiary.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The change will be effective from 1 April next year, and all of the subsidiary’s functions, except manufacturing and production technologies and marketing approvals, will be shifted to Daiichi Sankyo.

The subsidary will be involved in contract manufacturing of vaccines, biologics and investigational drugs.

“All of the subsidiary’s functions, except manufacturing and production technologies and marketing approvals, will be shifted to Daiichi Sankyo.”

Kitasato Daiichi Sankyo Vaccine was founded in 2011 as a joint venture (JV) between Daiichi Sankyo and the Kitasato Institute.

The JV’s operations include research and development (R&D), production and the sale of vaccines to prevent and treat verioud infectious diseases in humans.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Kitasato Vaccine was created as a wholly owned subsidary in November last year during a review of its vaccine business structure.

After the integration, the division focussed on the quality and stable supply of vaccines, along with the R&D and commercialisation of new products.

Daiichi Sankyo is a research-based pharmaceutical company involved in making generic pharmaceuticals, vaccines and over-the-counter medicines.

With operations across the US, Japan and Europe, the company has various other subsidiaries, including Luitpold Pharmaceuticals, Plexxikon, Daiichi Sankyo Ilac Ticaret, Daiichi Sankyo UK and Daiichi Sankyo RD Novare.